Guerbet SA is a French pharmaceutical group specializing in the manufacture and marketing of contrast agents for medical imaging. Founded in 1926 by André Guerbet, the company traces its roots to the ... Guerbet SA is a French pharmaceutical group specializing in the manufacture and marketing of contrast agents for medical imaging. Founded in 1926 by André Guerbet, the company traces its roots to the discovery of Lipiodol, the first iodinated X-ray contrast agent in 1901, and has since become a global leader supporting healthcare professionals in diagnostic and interventional imaging. Its product portfolio includes well-known brands such as Dotarem for MRI, Xenetix and Optiray for X-ray imaging, Lipiodol for various applications, and newer innovations like Elucirem (Gadopiclenol), approved by the FDA in 2022 for MRI contrast enhancement. Guerbet SA operates manufacturing facilities across France, Ireland, Canada, the United States, Macedonia, and Brazil, employing around 2,700 people worldwide and generating significant revenues in the growing contrast media market valued at $6.19 billion in 2023. As a société anonyme listed on Euronext Paris, it maintains a governance structure with a Board of Directors and Executive Committee, focusing on innovation, research, and industrial operations to advance radiology and medical imaging solutions. Guerbet SA plays a key role in the healthcare sector, particularly in medical devices for diagnostic purposes.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Group Entities data not yet covered for Guerbet

We have not yet reviewed Guerbet's disclosures for Group Entities data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Guerbet's data?

Start your 30-day free trial to request a data review for Guerbet.

Start Free Trial

Legal Center Contact Us